Latest News and Press Releases

Admission to Trading on Euronext Brussels This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis,...

Publication of Supplementary Prospectus This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis,...

Issue price of new ordinary shares to Cosmo in para 8 should be in EUROS rather than GBP and details of Cosmo’s holding post the issue has been added as a final para Correction - Acacia Pharma...

Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ €5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them Cambridge, UK and Indianapolis, US – 13 October...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them Cambridge, UK and Indianapolis, US – 13 October...

  Issue of Shares to Employee Benefit Trust This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and...

Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™ This announcement contains inside information for the...

      ·BYFAVO expected to be commercially available in the US before the end of the year             This announcement contains inside information for the purposes of Article 7 of the Market Abuse...

Acacia Pharma’s BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV) This announcement...